Navigation Links
Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
Date:5/27/2009

Small Molecule Stem Cell Modulator Administered in Dual Cord Blood Transplant for Hematologic Malignancy

LA JOLLA, Calif., May 27 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that the first patient has been treated in a Phase 1b clinical trial of FT1050, a small molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem cell (HSC) number and function through its activation of key pathways that guide cell fate. The study, which is being conducted at the Dana-Farber Cancer Institute in Boston, Massachusetts, will determine the safety and tolerability of introducing FT1050 during the standard course of dual umbilical cord blood transplant in adult patients with hematologic malignancies, such as leukemia and lymphoma, who have undergone nonmyeloablative conditioning therapy. Fate Therapeutics is developing FT1050 to improve the overall efficiency of HSC treatment by enhancing HSC proliferation and homing to the bone marrow.

"The mission of Fate Therapeutics is to develop small molecules and biologics that modulate adult stem cells within the body for regenerative medicine," said Paul Grayson, president and CEO of Fate Therapeutics. "As our first SCM clinical candidate, FT1050 represents the initial step in our approach - using a small molecule to treat cells ex vivo but creating an in vivo regenerative effect. With FT1050, we are trying to affect stem cell biology in the body, improving the reconstitution of a patient's blood and immune system."

"For patients who need hematopoietic stem cell support, time is of the essence," said Corey Cutler M.D., M.P.H., F.R.C.P.C., assistant professor of medicine, Dana-Farber and Harvard Medical School, and leader of the clinical study. "However, many patients do not have a suitably matched donor, either from a sibling or from an unrelated volunteer in t
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Commonwealth Cornerstone Group (CCG) today ... Credits transaction on Tuesday to help fund the expansion and ... in Sharon . PHN ... Pennsylvania . It is the largest employer in ... than 150 people on staff. Currently, PHN Sharon ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
(Date:12/24/2014)... International Trade Commission (ITC) issued its final decision in the ... notice issued on December 23, the ITC ruled in favor ... was invalid. BMC President, James Xu ... with the ITC,s decision in this case. This victory for ... very beginning on the key patents in the case. ResMed ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... procedure ... ... that four presentations at the Heart Rhythm Society,s 2008,Scientific Sessions reported ... findings aligned well with each,other and supported previous experience from the ...
... increased FDA scrutiny,around new medicines and heightened competition ... science staff have to be even,more delicate when ... With less products making it through development,communications for ... on to favorably impact,launch success. Marketers see coordination ...
Cached Medicine Technology:Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients 2Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients 3New Pharma Business Model Increases Pressure on Staff Communicating Trial Data 2
(Date:12/25/2014)... Aliso Viejo, California (PRWEB) December 25, 2014 ... the release of ProFire 5k. A fully customizable business ... X . , “Adding the ProFire 5k business tool, ... style” Said Christina Austin, CEO of Pixel Film Studios. ... the look and style to add professionalism to a ...
(Date:12/25/2014)... 25, 2014 Each year trauma accounts ... million hospital admissions across the nation (according to ... CDC’s National Hospital Ambulatory Medical Care Survey ... conducted in 2010. They estimated that there were between ... in a primary diagnosis of broken bone or fracture. ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those ... During the holiday season, AlignLife looks forward to their annual ... Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It brings our patients ... we are able to give kids toys for Christmas who ... the generosity of our patients." , The 70 toys were ...
(Date:12/24/2014)... finds applications in a large number of fields of ... and research for metabolic and genetic disorders. It is ... techniques for the discovery and development of cancer biomarkers. ... growing worldwide. In 2012, there were 14.1 million new ... people living with cancer (within five years of diagnosis) ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and ... under $150 . All these items are brand new; they ... already been updated with the new range of high quality ... far. All iFitDress.com’s designs are made according to the latest ... materials. Every outfit from the company is handpicked by skilled ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... Chairman, Tony Strange Appointed to CEO position and Will Join ... , MELVILLE, N.Y., Nov. 18 /PRNewswire-FirstCall/ -- ... a leading provider of comprehensive home health services, announced today ... plan. Effective January 1, 2009, Tony Strange will become ...
... by contact with blood, respiratory secretion , , TUESDAY, Nov. ... of a tick-borne disease called granulocytic anaplasmosis (HGA), which ... described in a study by researchers at China,s National ... the first known report of human-to-human transmission of HGA. ...
... of Michigan is,asking Attorney General Mike Cox to stand ... that are,included in a compromise on health insurance reform ... conference committee of the Michigan House and,Senate. , ... has a vested interest in ensuring that all,Michigan consumers ...
... allergic reactions, other problems have surfaced with these products, ... American women who turn to cosmetic treatments called dermal ... to the health risks these products pose, an advisory ... Tuesday. , The panel of independent experts urged the ...
... SEATTLE, Nov. 18 Just in time ... new Web site http://www.ShopForCancerCures.org to,benefit ... Center,( http://www.fhcrc.org ) and 10 other world-class ... ( http://www.cancerresearchalliance.org ). A portion of,each purchase ...
... ability to live and function when enrolled in tailored interventions ... get elderly cancer survivors to eat better and exercise more ... a new study says. , The Texas study found ... ability, lost weight and body mass when enrolled in a ...
Cached Medicine News:Health News:Gentiva Health Services Confirms Management Succession 2Health News:Gentiva Health Services Confirms Management Succession 3Health News:Gentiva Health Services Confirms Management Succession 4Health News:China Documents First Case of Tick-Borne Disease Spread 2Health News:Blue Cross Blue Shield of Michigan Calls for Attorney General to Support Stronger Regulation of Commercial Insurers; Protections for Consumers; and Financially Stable Insurance Market 2Health News:Wrinkle Fillers Need Better Label Warnings: FDA Panel 2Health News:Wrinkle Fillers Need Better Label Warnings: FDA Panel 3Health News:Fred Hutchinson Cancer Research Center Benefits From Shopping Site 2Health News:Fred Hutchinson Cancer Research Center Benefits From Shopping Site 3Health News:Home-Based Programs Benefit Older Cancer Survivors 2
The rubber, whistle tip catheter with thumb valve has two side eyes to help minimize trauma....
Soft and flexible whistle tip catheter with 2 eye configuration. "Chimney" connector with standard tapered fit and thumb control. Available in sizes 6 18 French. Packaged straight....
... Patient Trauma and Increase Staff Protection With Medline's ... Fr, 14 Fr, 16 Fr and 18 Fr), ... products in the U.S. We manufacture most of ... meets or exceeds our customers' expectations. We manufacture, ...
... Catheters are available in ... atraumatic DeLee tip with staggered ... tip. Two types of catheter ... deliver easy fingertip control with ...
Medicine Products: